The role of liquid biopsy in predicting post-operative recurrence of non-small cell lung cancer
- 1 April 2018
- journal article
- research article
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 10 (S7) , S838-S845
Abstract
Background: Radical resection is the cornerstone for patients with early stage of non-small cell lung cancer (NSCLC). However, fatal disease recurs in about 30–70% of resected cases. The circulating tumor cells (CTCs) is one of the main causes of recurrence of cancer. Circulating tumor DNA (ctDNA) is also a potential predictive biomarker of recurrence in patients with early stage NSCLC. A meta-analysis was conducted to identify the prognostic value of the CTCs and ctDNA in predicting the disease recurrence after surgery of NSCLC patients. Methods: Electronic databases were comprehensively searched for eligible studies. A random effects model was used. The primary endpoint was the hazards ratio (HR) for the disease-free survival (DFS) between CTCs/ctDNA positive and negative groups. The relative risks (RR) of one and two-year recurrence rate between CTCs/ctDNA positive and negative groups were also calculated. Results: A total of 5 studies involving 351 patients were included, in which 3 were studies on CTCs and 2 were ctDNA. Our result revealed that positive peripheral blood CTCs (HR, 3.37; 95% CI: 2.28–4.96; Pvs. 18.2%; RR 3.28; Pvs. 44%; RR 1.80; P=0.06) years recurrence rate were higher in CTCs positive group compared with the negative group, respectively. The same result was also observed in ctDNA positive versus negative groups of 1 (77.9% vs. 8.3%; RR 9.05; P=0.001) and 2 (85.6% vs. 8.3%; RR 9.63; PConclusions: Both postoperative CTCs and ctDNA are promising predictive biomarkers of early tumor recurrence in NSCLC patients. In addition, detection based on ctDNA seems to be more sensitive than CTCs.Keywords
This publication has 28 references indexed in Scilit:
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolutionNature, 2017
- Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network, 2017
- Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancerCancer Medicine, 2017
- Circulating Tumor Cells Identify Early Recurrence in Patients with Non-Small Cell Lung Cancer Undergoing Radical ResectionPLOS ONE, 2016
- Mutation tracking in circulating tumor DNA predicts relapse in early breast cancerScience Translational Medicine, 2015
- Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic TreatmentCancers, 2014
- Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication biasJournal of Cranio-Maxillofacial Surgery, 2011
- Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non‐small‐cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell methodInternational Journal of Cancer, 2010
- Aggregate data meta‐analysis with time‐to‐event outcomesStatistics in Medicine, 2002
- Extracting summary statistics to perform meta-analyses of the published literature for survival endpointsStatistics in Medicine, 1998